Amgen Files Proxy Statement for Annual Meeting

TL;DR

Amgen dropped its proxy statement - shareholders vote soon on directors & exec pay.

AI Summary

Amgen Inc. filed its definitive proxy statement (DEFA14A) on May 3, 2024, for its upcoming annual meeting. The filing details the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors.

Why It Matters

This filing provides shareholders with crucial information to make informed voting decisions on company leadership and important corporate matters at the upcoming annual meeting.

Risk Assessment

Risk Level: low — This is a routine filing for a public company's annual meeting and does not contain new material financial information or significant strategic shifts.

Key Players & Entities

• AMGEN INC (company) — Registrant
• 0001193125-24-130671 (filing_id) — Accession Number
• 20240503 (date) — Filing Date
• ONE AMGEN CENTER DRIVE (address) — Business Address
• THOUSAND OAKS (location) — City
• CA (state) — State
• 91320 (zip_code) — ZIP Code
• 001-37702 (company_id) — SEC File Number

FAQ

From the Filing

0001193125-24-130671.txt : 20240503 0001193125-24-130671.hdr.sgml : 20240503 20240503160229 ACCESSION NUMBER: 0001193125-24-130671 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20240503 DATE AS OF CHANGE: 20240503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 24912891 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 DEFA14A 1 d809085ddefa14a.htm DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑  Filed by the registrant      ☐  Filed by a party other than the registrant Check the appropriate box:     ☐      Preliminary Proxy Statement ☐   CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☐   Definitive Proxy Statement ☑   Definitive Additional Materials ☐   Soliciting Material Pursuant to Section 240.14a-12 AMGEN INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of filing fee (check the appropriate box):     ☑      No fee required. ☐   Fee paid previously with preliminary materials. ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0- 11. Subsequent to this filing, the following letter was sent by Amgen Inc. to certain institutional holders of our common stock. We encourage our stockholders to similarly consider this letter when casting their vote. Amgen Inc. 1 Amgen Center Drive Thousand Oaks, CA 91320 USA (805) 447-1000 amgen.com «DATE» «SALUTATION» «FIRSTNAME» «LASTNAME» «COMPANYNAME» «ADDRESS1» «ADDRESS2» «CITY», «STATE» «ZIPCODE» Dear «SALUTATION» «LASTNAME»: I want to take a moment to thank you for your investment in Amgen. I typically write around this time of year to provide a short summary of Amgen’s Board of Directors’ recommendations for our Annual Meeting of Stockholders. 2023 was another year of strong execution of our strategy . We acquired Horizon Therapeutics plc (Horizon), advanced our innovative pipeline, and delivered strong performance. Execution of Our Strategy The core of Amgen’s strategy is innovation. More specifically, we seek to provide first- or-best-in-class medicines that make a significant difference for patients suffering from serious diseases. Some of these innovative medicines are developed internally and some are sourced externally. · In 2023, we acquired Horizon , a leading provider of innovative medicines to treat rare inflammatory diseases. The medicines we acquired are all very early in their lifecycles and, by leveraging Amgen’s world-class biologics capabilities, decades of experience in inflammation, and extensive global presence, we believe they have significant growth potential. · Today, our portfolio spans four therapeutic areas: General Medicine ; Oncology ; Inflammation ; and, now, Rare Disease . In each area, we have numerous well-established products currently on the market, promising new innovative medicine